IMUImugene Limited

IMU Stock Price, Valuation & Chart | Imugene Limited

Compare

$0.040+0.00 (+5.88%)

At close · 16 Oct 2026, 05:10 am

Sector: Healthcare Industry: Biotechnology Website

Overview Financials Dividends Ratios

IMU Historical price chart

IMU Key Stats

Market Capitalization19.76M

PE Ratio-0.11

EPS-0.32

Trading Volume2.27M

Today's High/Low0.04/0.03

Dividend Yield0.00

52 Week High/Low0.43/0.03

Shares Outstanding548.90M

IMU Financial Statement

IMU Analyst ratings

Buy

Strong buy

Buy

Hold

Sell

Strong sell

Based on 1 analyst giving stock ratings to IMU in the past 3 months.

IMU Analysis & performance metrics

IMU Company profile

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors…

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase…

IMU Management team

Name

Position

Bradley Glover M.B.A., Ph.D.COO

Chief Operating Officer

Joseph Paul Woodard Jr., M.D.

Chief Medical Officer

John Byon M.D.

Senior Vice President of Clinical Development

Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICDCFO

Chief Financial Officer & Company Secretary

Ursula McCurry

Chief Clinical Operations Officer

Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD

Executive Chairman

Leslie ChongCEO

Chief Executive Officer, MD & Executive Director

Name

Position

Bradley Glover M.B.A., Ph.D.COO

Chief Operating Officer

Joseph Paul Woodard Jr., M.D.

Chief Medical Officer

John Byon M.D.

Senior Vice President of Clinical Development

Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICDCFO

Chief Financial Officer & Company Secretary

Ursula McCurry

Chief Clinical Operations Officer

Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD

Executive Chairman

Leslie ChongCEO

Chief Executive Officer, MD & Executive Director

Management Team

Bradley Glover M.B.A., Ph.D.COO

Chief Operating Officer

Joseph Paul Woodard Jr., M.D.

Chief Medical Officer

John Byon M.D.

Senior Vice President of Clinical Development

Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICDCFO

Chief Financial Officer & Company Secretary

Ursula McCurry

Chief Clinical Operations Officer

Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD

Executive Chairman

Leslie ChongCEO

Chief Executive Officer, MD & Executive Director

Management

Bradley Glover M.B.A., Ph.D.COO

Chief Operating Officer

Joseph Paul Woodard Jr., M.D.

Chief Medical Officer

John Byon M.D.

Senior Vice President of Clinical Development

Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICDCFO

Chief Financial Officer & Company Secretary

Ursula McCurry

Chief Clinical Operations Officer

Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD

Executive Chairman

Leslie ChongCEO

Chief Executive Officer, MD & Executive Director

Total 7 executives

IMU Frequently asked questions

What is Imugene Limited (IMU) Stock Price?

Current stock price of Imugene Limited (IMU) stock is $0.040. The stock price is +5.88% higher in the session. The intraday range can be seen from this page. Volume of Imugene Limited (IMU) stock is 2.27M.

Last updated at 16 Oct 2026, 05:10 am.

Why is the Imugene Limited (IMU) stock price going up or down today?

The stock price of Imugene Limited (IMU) can change with earnings, company news, and overall market sentiment. Imugene Limited operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Imugene Limited stock expensive at its current price?

Whether Imugene Limited looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for IMU on this page is -0.11. EPS on this page is -0.32. Compare those figures with peers and growth expectations before deciding if the current Imugene Limited price is justified.

How has the stock price of Imugene Limited (IMU) performed historically?

Historical performance for Imugene Limited (IMU) is shown on the price chart on this page. Review multi-period moves alongside volume to see how IMU reacted to past earnings and market events.

Should I buy Imugene Limited (IMU) stock, at this price?

Buying Imugene Limited (IMU) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.